2-[1-(4-Piperonyl)piperazinyl]benzothiazole5-HT4 agonist. Also 5-HT3 antagonist CAS# 155106-73-3 |
2D Structure
- (24R)-MC 976
Catalog No.:BCC1289
CAS No.:112828-09-8
- (24S)-MC 976
Catalog No.:BCC1291
CAS No.:112849-14-6
- 1alpha, 25-Dihydroxy VD2-D6
Catalog No.:BCC1299
CAS No.:216244-04-1
- 1alpha, 24, 25-Trihydroxy VD2
Catalog No.:BCC1298
CAS No.:457048-34-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 155106-73-3 | SDF | Download SDF |
PubChem ID | 127902 | Appearance | Powder |
Formula | C19H19N3O2S | M.Wt | 353.44 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in DMSO with gentle warming | ||
Chemical Name | 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-1,3-benzothiazole | ||
SMILES | C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC5=CC=CC=C5S4 | ||
Standard InChIKey | BYHKGNWKJMGHGE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H19N3O2S/c1-2-4-18-15(3-1)20-19(25-18)22-9-7-21(8-10-22)12-14-5-6-16-17(11-14)24-13-23-16/h1-6,11H,7-10,12-13H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
2-[1-(4-Piperonyl)piperazinyl]benzothiazole Dilution Calculator
2-[1-(4-Piperonyl)piperazinyl]benzothiazole Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8293 mL | 14.1467 mL | 28.2933 mL | 56.5867 mL | 70.7334 mL |
5 mM | 0.5659 mL | 2.8293 mL | 5.6587 mL | 11.3173 mL | 14.1467 mL |
10 mM | 0.2829 mL | 1.4147 mL | 2.8293 mL | 5.6587 mL | 7.0733 mL |
50 mM | 0.0566 mL | 0.2829 mL | 0.5659 mL | 1.1317 mL | 1.4147 mL |
100 mM | 0.0283 mL | 0.1415 mL | 0.2829 mL | 0.5659 mL | 0.7073 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6-ethyl-3-methyl-4-oxo-4H-pyran-2-carboxylic acid
Catalog No.:BCC8270
CAS No.:1551-49-1
- 11-Deoxyalisol B
Catalog No.:BCN3359
CAS No.:155073-73-7
- 24,25-Dihydroxycycloartan-3-one
Catalog No.:BCN1692
CAS No.:155060-48-3
- SM-21 maleate
Catalog No.:BCC6780
CAS No.:155059-42-0
- N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide
Catalog No.:BCC6784
CAS No.:155054-42-5
- 4-Hydroxy-3-(3-methyl-2-butenoyl)-5-(3-methyl-2-butenyl)benzoic acid
Catalog No.:BCN1554
CAS No.:155051-85-7
- Usaramine
Catalog No.:BCN2121
CAS No.:15503-87-4
- Isatidine
Catalog No.:BCN2120
CAS No.:15503-86-3
- Pancuronium dibromide
Catalog No.:BCC4578
CAS No.:15500-66-0
- Ac-Arg-OH.2H2O
Catalog No.:BCC2855
CAS No.:155-84-0
- Rhaponiticin
Catalog No.:BCN5392
CAS No.:155-58-8
- Methscopolamine
Catalog No.:BCC4577
CAS No.:155-41-9
- Rosiglitazone maleate
Catalog No.:BCC2262
CAS No.:155141-29-0
- Plerixafor 8HCl (AMD3100 8HCl)
Catalog No.:BCC4447
CAS No.:155148-31-5
- Plerixafor octahydrobromide
Catalog No.:BCC9123
CAS No.:155148-32-6
- Physapruin A
Catalog No.:BCN7576
CAS No.:155178-03-3
- Cordifolioside A
Catalog No.:BCN8224
CAS No.:155179-20-7
- Cinnamylideneacetic acid
Catalog No.:BCN7777
CAS No.:1552-94-9
- 4-(Dimethylamino)cinnamic acid
Catalog No.:BCN5031
CAS No.:1552-96-1
- 7alpha,15-Dihydroxydehydroabietic acid
Catalog No.:BCN7672
CAS No.:155205-64-4
- Methyl 7,15-dihydroxydehydroabietate
Catalog No.:BCN1693
CAS No.:155205-65-5
- Bimatoprost
Catalog No.:BCC4948
CAS No.:155206-00-1
- Ritonavir
Catalog No.:BCC3620
CAS No.:155213-67-5
- Peraksine
Catalog No.:BCN1694
CAS No.:15527-80-7
Roles of serotonin receptor subtypes for the antinociception of 5-HT in the spinal cord of rats.[Pubmed:15476746]
Eur J Pharmacol. 2004 Oct 19;502(3):205-11.
The contribution of 5-HT (5-hydroxytryptamine) receptor subtypes to the antinociception produced by intrathecal 5-HT in the formalin test was investigated in rats. Intrathecal 5-HT suppressed both phases of behaviors produced by 5% formalin, and this was blocked by antagonists for 5-HT(1B) (3-[3-(Dimethylamino)propyl]-4-hy-droxy-N-[4-(4-pyridinyl)phenyl]benzamide dihydrochloride, GR 55562), 5-HT(2C) (N-ormethylclozapine/8-Chloro-11-(1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine, D-MC), 5-HT3 (1-Methyl-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1H-indazole-3-carboxamide maleate, LY-278,584) and 5-HT4 receptors (4-Amino-5-chloro-2-metho-xy-benzoic acid 2-(diethylamino)ethyl ester hydrochloride, SDZ-205,557), but not the 5-HT(1D) receptor antagonist 3-[4-(4-Chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol hydrochloride (BRL 15572). The 5-HT(1A) receptor antagonist N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]-N-2-pyridinyl-cyclohexanecarboxamide maleate (WAY-100635) decreased only the second phase antinociception of 5-HT. Intrathecal administration of agonists for 5-HT(1A) (3-(N,N-Dipropylaminoethyl)-1H-indole-5-carboxamide maleate, Dipropyl-5CT), 5-HT(1B) (7-Trifluoromethyl-4(4-met-hyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline maleate, CGS-12066A), 5-HT(2C) (6-Ch-loro-2-(1-piperazinyl)pyrazine hydrochloride, MK 212), 5-HT3 (N-(3-Chlorophenyl)imidodicarbonimidic diamide hydrochloride, m-CPBG) and 5-HT4 receptors (2-[1-(4-Piperonyl)piperazinyl]benzothiazole, BZTZ) suppressed both phases of the formalin response. The results of the present study indicate that spinal 5-HT(1B,) 5-HT(2C,) 5-HT3 and 5-HT4 receptors, but not the 5-HT(1D) receptor, mediate antinociception produced by 5-HT in the formalin test. The relevance of the 5-HT(1A) receptor is less clear because of the different effects of antagonist and agonist.
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.[Pubmed:8176710]
J Med Chem. 1994 Apr 29;37(9):1320-5.
New 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives were prepared and tested as 5-HT3 receptor antagonists. Some of the new compounds antagonized the effect of 5-HT at the longitudinal muscle myenteric plexus (LMMP) preparation of the guinea pig ileum, and two benzothiazole derivatives, compounds 2e and 2f, were more potent than ondansetron in this regard. However, these two compounds were much weaker than the typical 5-HT3 receptor antagonist as displacers of [3H]BRL-43694 binding to rat cerebral cortex homogenates or as antagonists of the bradycardia response to 5-HT in the anaesthetized rat. Like the prokinetic agent cisapride, some of the new compounds enhanced gastric emptying in rats. Compound 2f not only markedly enhanced gastric emptying but was also a potent agonist at the isolated rat oesophageal tunica muscularis mucosae, a preparation sensitive to 5-HT4 receptor stimulation, and enhanced the twitch response in the LMMP preparation. The latter effect was blocked by a high concentration of tropisetron or by previous desensitization with 5-methoxytryptamine. Compound 2f appears to show a promising pharmacological profile as a potential gastrokinetic agent.